Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 49Neoplasm Metastasis 47Multiple Myeloma 40Breast Neoplasms 33Prostatic Neoplasms 31Colorectal Neoplasms 27Lymphoma 26Lung Neoplasms 26Leukemia, Lymphocytic, Chronic, B-Cell 24Pancreatic Neoplasms 22Myelodysplastic Syndromes 22Lymphoma, Large B-Cell, Diffuse 21Triple Negative Breast Neoplasms 19Ovarian Neoplasms 17Melanoma 17Carcinoma, Non-Small-Cell Lung 17Burkitt Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Carcinoma, Renal Cell 15Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Glioma 13Neuroblastoma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Sarcoma 11Lymphoma, Non-Hodgkin 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Myeloproliferative Disorders 10

Interventions

Rituximab 7Vemurafenib 4Cyclophosphamide 4Cladribine 4Specimen Handling 3Biopsy 3obinutuzumab 2ibrutinib 2fludarabine phosphate 2fludarabine 2binimetinib 2Diphenhydramine 2Dexamethasone 2Calcium Dobesilate 2CT-P10 2Acetaminophen 2venetoclax 1tovorafenib 1polatuzumab vedotin 1pembrolizumab 1immunotoxin HA22 1encorafenib 1dexamethasone acetate 1dexamethasone 21-phosphate 1brexucabtagene autoleucel 1auricularum 1acalabrutinib 1Whole-Body Irradiation 1Valganciclovir 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × Biopsy × 1 year × Clear all
NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06311227 2026-05-13

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡